The tumour cells in DLBCL are considered to be derived from activated B-cells (ABC) or germinal centre B-cells (GCB) based on gene expression profiling (GEP). 5 Several immunohistochemical algorithms have been developed as substitutes and applied with varying concordance with GEP. [6] [7] [8] The Hans algorithm is the most commonly used algorithm and has a reasonable correlation with GEP, 6 based on the immunohistochemical staining results of three proteins: CD10, BCL-6 and MUM1.
In addition, other tumour cell markers have prognostic impact in DLBCL. High expression of P53 and double expression of MYC and BCL2 are associated with inferior outcome in DLBCL. 10, 11 Gene rearrangements of MYC and BCL2 and/or BCL6, referred to as "double-hit" lymphomas, are recognised as a separate entity with dismal outcome according to the 2016 WHO classification of Tumours of Haematopoietic and Lymphoid Tissues. 9 In this study, we evaluated clinical characteristics and tumour cell markers in DLBCL patients with the aim to characterise particularly those with abdominal lymph node involvement taking into consideration the site of lymph nodes involved and study their association with clinical outcome.
| MATERIAL S AND ME THODS

| Patients
This study retrospectively retrieved 249 patients (age range Formalin-fixed, paraffin-embedded (FFPE) diagnostic biopsies were reviewed by two haematopathologists (RMA, AAM). Tumours were classified as DLBCL according to the 2008 WHO classification. 9 This study was approved by the Regional Ethical Review Board in Uppsala, Sweden (EPN 233/2014).
| Radiological evaluation
All patients were investigated using a contrast-enhanced computed tomography (CT) of the thorax and abdomen. PET was not performed in the majority of patients included. The images were independently reviewed by a radiologist (PG) with 6 years of experience, on a picture archiving and communication system (PACS). On axial images, the long axis and short axis of abdominal lymph nodes were measured. They were defined as pathological abdominal lymphadenopathy if two or more of them had a long axis ≥ 15 mm 12 and a short axis >10 mm, 13 and as "bulky" if the single lymph node or the conglomerate mass of lymph nodes was greater than 75 mm in diameter. 14, 15 According to the localisation of the bulky mass, the involvement was defined as "abdominal" if the bulky disease was situated below the diaphragm.
| Immunohistochemistry
Immunohistochemical stainings were performed on FFPE tissue off values of 70% and 40% were used for BCL2 and MYC, respectively, as previously described. 16 
| Statistical analyses
| RE SULTS
| Descriptive data
Radiological examination revealed pathologically enlarged lymph nodes in the abdomen in 156/249 (63%) of the patients. Patients with abdominal lymph node involvement (n = 156) more often had TA B L E 1 Clinical characteristics and tumour cell markers in 249 DLBCL patients who were reviewed radiologically and divided into patients with abdominal lymph node involvement and patients with no abdominal lymph node involvement
Parameters
Whole cohort
Abdominal lymph node involvement n (%)
No abdominal lymph node involvement n (%) P-value b
All 11 In the whole cohort, DEL and high expression of P53 were associated with inferior outcome. The negative prognostic impact of P53 and DEL has previously been confirmed by others. 10, 11 In multivariate analysis, high expression of P53 was an independent negative prognostic indicator, which is in line with previous studies. 10, 17 However, there was no difference in the expression of P53 in DLBCL patients with abdominal lymph node involvement compared to patients without lymph node involvement in the abdomen. Nor were there any differences in outcome regarding GCB or non-GCB phenotypes, which has also been shown by others. 18 However, other studies have found that patients with non-GCB have an inferior survival outcome compared to patients with GCB. 19 The prognostic impact of bulky disease in DLBCL has declined since the introduction of rituximab in the treatment of DLBCL. 20, 21 In our study, DLBCL patients with abdominal lymph node involvement had a higher frequency of bulky disease than patients without lymph node involvement in the abdomen, but the bulky disease per se was not associated with worse prognosis in the whole cohort.
| Survival
| D ISCUSS I ON
Interestingly, we found a group of patients where abdominal However, there are many factors that determine the site of biopsy poor prognosis of this group. 18 F-FDG PET-CT is recommended as the gold standard radiological examination for staging and assessment of treatment response in lymphoma. 22 However, abnormal uptake by causes other than lymphoma should be carefully excluded. 23, 24 Furthermore, the size of lymph nodes does not appear to be a mandatory indicator of disease involvement. 25,26 18 F-FDG PET was not performed routinely in our cohort, and consequently, it was only possible to re-evaluate CT images. 27 The reason why we did not include PET data or only patients with PET results was to avoid a selection bias, since younger patients were more often candidates for PET. Today, the national guidelines for high-grade B-cell lymphoma state that PET-CT should be done, although this is not always performed.
It is worth mentioning that a weakness of our study is that it was a single-centre retrospective study and is somewhat hampered by the rather low number of cases included. If abdominal lymph node involvement is an independent prognostic factor associated with dismal survival outcome in DLBCL, patients need to be investigated by more comprehensive studies. In addition, the insufficient tissue samples in cases where diagnosis was made on core needle biopsy made it not possible to perform all immunohistochemical stainings in these patients.
Nor was further analysis, such as rearrangement analysis of MYC and BCL2 and other molecular analyses possible due to the sparse material.
This emphasises the need of improved targeting and increased sampling volumes in percutaneous and endoscopic biopsies in order to study the supposed distinct biologic composition in nodal abdominal DLBCL.
In summary, we found that DLBCL patients with lymph node involvement in the abdomen had inferior prognosis (LSS) and more aggressive behaviour compared to patients without abdominal nodal involvement, reflected in both the clinical and the biological characteristics. Patients with histopathologically proven abdominal nodal disease have a more dismal outcome (OS, LSS and PFS). Thus, the site of lymph node involvement might have prognostic impact in DLBCL.
